Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efprezimod alfa - Merck & Co

Next Previous
Drug Profile

Efprezimod alfa - Merck & Co

Alternative Names: CD24-Fc; CD24-Fc-IgG; CD24Fc-fusion protein; MK-7110; Recombinant CD24 IgG1 Fc fusion protein; Recombinant human CD24FcIg

Latest Information Update: 22 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoImmune
  • Developer National Institute of Neurological Disorders and Stroke; OncoImmune
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; NF-kappa B inhibitors; SIGLEC10 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Graft-versus-host disease
  • Phase II Dyslipidaemias
  • Phase I/II Solid tumours
  • No development reported Autoimmune disorders
  • Discontinued COVID 2019 infections

Most Recent Events

  • 22 Apr 2022 University of California, Davis in collaboration with OncoImmune and National Cancer Institute terminates a phase I/II TIRAEC trial in Solid tumors (Late-stage disease, Second-line therapy or greater) in USA because of change in sponsor (NCT04552704)
  • 05 Nov 2021 Merck Sharp & Dohme terminates the phase III CATHY trial for Graft-versus-host disease (Prevention) in USA (IV)(NCT04095858)
  • 05 Nov 2021 Merck Sharp & Dohme terminates the phase III CATHY trial for Graft-versus-host disease (Prevention) in USA (IV)(NCT04976699)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top